Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.

about

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.

Item

http://www.wikidata.org/entity/Q47164735

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Durability of switch regimens ...... logically suppressed patients.

@en

Durability of switch regimens ...... logically suppressed patients.

@nl

type

Item

label

Durability of switch regimens ...... logically suppressed patients.

@en

Durability of switch regimens ...... logically suppressed patients.

@nl

prefLabel

Durability of switch regimens ...... logically suppressed patients.

@en

Durability of switch regimens ...... logically suppressed patients.

@nl

P1476

Durability of switch regimens ...... logically suppressed patients.

@en

P2093

Alessia Carbone

http://www.w3.org/2001/XMLSchema#string

Andrea Poli

http://www.w3.org/2001/XMLSchema#string

Laura Galli

http://www.w3.org/2001/XMLSchema#string

Marco Ripa

http://www.w3.org/2001/XMLSchema#string

Nadia Galizzi

http://www.w3.org/2001/XMLSchema#string

Silvia Nozza

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999).

An internationally generalizable risk index for mortality after one year of antiretroviral therapy.

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b,

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.

Hepatotoxicity in patients prescribed efavirenz or nevirapine.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

P2888

s12879-017-2831-9

P304

723

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12879-017-2831-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092735322

http://www.w3.org/2001/XMLSchema#string

P698

29145807

http://www.w3.org/2001/XMLSchema#string

P921

virology

P932

5691866

http://www.w3.org/2001/XMLSchema#string